XML 235 R191.htm IDEA: XBRL DOCUMENT
v3.22.4

Off balance sheet commitments - Additional Information (Details) € in Millions, $ in Millions |  |  |  |  |  |  |  |  |  |  |  |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 19, 2022 USD ($) | Nov. 08, 2022 USD ($) | Oct. 04, 2022 USD ($) | Sep. 27, 2022 USD ($) | Aug. 17, 2022 USD ($) | Jul. 05, 2022 USD ($) | Mar. 29, 2022 USD ($) | Mar. 15, 2022 EUR (€) | Mar. 02, 2022 USD ($) | Jan. 11, 2022 USD ($) | Jan. 07, 2022 USD ($) molecule | Feb. 27, 2017 EUR (€) | Mar. 31, 2022 | Dec. 31, 2022 USD ($) | Dec. 31, 2022 USD ($) | Dec. 31, 2016 target | Dec. 31, 2022 EUR (€) | Mar. 29, 2022 EUR (€) target | Dec. 31, 2021 EUR (€) | Apr. 08, 2021 USD ($) | Dec. 31, 2020 EUR (€) | Feb. 28, 2014
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to research and development relating to projects in research phase | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 18,000 |  | € 6,700 |  |  |
Commitments related to research and development payments contingent upon attainment of sales targets | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 18,500 |  | 8,100 |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,800 |  | 5,800 |  |  |
Commitments related to attainment of regulatory and sales milestones for commercialized products | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,600 |  | 4,200 |  |  |
Cumulative development costs incurred | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,400 |  |  |
Total credit facilities | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 8,000 |  | 8,000 |  | € 8,000 |
Commitments received in respect of disposals proceeds receivable and contingent consideration on divestments |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,000.0 | $ 1,000.0 |  |  |  |  |  |  |
Sanofi Belgium |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  | 1,000 |  |  |
Kymab |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to collaboration, discovery, development and commercialization agreements | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200 |  | 500 |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 350.0 |  |
World Health Organization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of pandemic vaccines agreed to transfer |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.50%
Percentage of pandemic vaccines agreed to reserve |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7.50%
Joint ventures |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of future development expense funded by other party |  |  |  |  |  |  |  |  |  |  |  | 5000.00% |  |  |  |  |  |  |  |  |  |
Dice Molecules |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Targets that encompass all diseases areas | target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 |  |  |  |  |  |
Lonza | Joint ventures |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Investments in joint ventures | € |  |  |  |  |  |  |  |  |  |  |  | € 300 |  |  |  |  |  |  |  |  |  |
Percentage of future development expense funded by company |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |
Amounts payable partners in collaboration agreements | € |  |  |  |  |  |  |  |  |  |  |  | € 600 |  |  |  |  |  |  |  |  |  |
Share of operating expenses and cost of production to joint partner payable period |  |  |  |  |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |  |  |  |  |
ABL Bio |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  | $ 75.0 |  |  |  |  |  |  |  |  |  |  |  |
ABL Bio | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  |  |  |  |  | $ 985.0 |  |  |  |  |  |  |  |  |  |  |  |
Adagene, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  | $ 17.5 |  |  |  |  |  |  |  |  |  |  |  |  |
Adagene, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  |  |  |  | $ 2,500.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Blackstone Life Sciences | Antibodies collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments related to maximum payments for projects under collaboration agreement | € |  |  |  |  |  |  |  | € 300 |  |  |  |  |  |  |  |  |  |  |  |  |  |
IGM Biosciences, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  | $ 150.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
IGM Biosciences, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of oncology targets under collaboration agreement | target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |
Number of immunology or inflammation targets under collaboration agreement | target |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |
Contingent consideration collaboration agreements | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 6,000 |  |  |  |
Skyhawk Therapeutics, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  | $ 54.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Skyhawk Therapeutics, Inc | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration collaboration agreements |  |  |  |  |  | $ 2,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
miRecule |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  | $ 20.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
miRecule | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration collaboration agreements |  |  | $ 400.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Innate Pharma SA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 25.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Innate Pharma SA | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration collaboration agreements | $ 1,400.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exscientia |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  | $ 100.0 |  |  |  |  |  |  |  |  |  |  |
Exscientia | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of novel small molecule candidates developed | molecule |  |  |  |  |  |  |  |  |  |  | 15 |  |  |  |  |  |  |  |  |  |  |
Commitments related to milestone payments for projects under collaboration agreements |  |  |  |  |  |  |  |  |  |  | $ 5,200.0 |  |  |  |  |  |  |  |  |  |  |
Atomwise |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  |  | $ 20.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atomwise | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration collaboration agreements |  |  |  |  | $ 1,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Scribe Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  |  |  | $ 25.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Scribe Therapeutics | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration collaboration agreements |  |  |  | $ 1,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Insilico Medicine |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment |  | $ 12.5 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Insilico Medicine | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration collaboration agreements |  | $ 1,200.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Regeneron Pharmaceuticals, INC | Antibodies collaboration agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Provisions and other non-current liabilities [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Commitments received for development costs | € |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 2,700 |  | € 2,900 |  |  |
Maximum additional profit-share, in percentage of Regeneron's quarterly profit (in percent) |  |  |  |  |  |  |  |  |  |  |  |  | 10.00% | 20.00% |  |  |  |  |  |  |  |
Percentage of cumulative development costs reimbursed |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 50.00% |  |  |  |  |  |  |

X
- Definition The amount of investments in joint ventures in an entity's separate financial statements. [Refer: Joint ventures [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2021-01-01 -Paragraph 10 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_InvestmentsInJointVentures
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The amount of undrawn borrowing facilities that may be available for future operating activities and to settle capital commitments. [Refer: Capital commitments] + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Name IAS -Number 7 -IssueDate 2021-01-01 -Paragraph 50 -Subparagraph a -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_a&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_UndrawnBorrowingFacilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amounts payable partners in collaboration agreements. + References No definition available. + Details
Name: | sny_AmountsPayablePartnersInCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Received For Development Costs + References No definition available. + Details
Name: | sny_CommitmentsReceivedForDevelopmentCosts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Commitments Related To Attainment Of Regulatory And Sales Milestones For Commercialized Products + References No definition available. + Details
Name: | sny_CommitmentsRelatedToAttainmentOfRegulatoryAndSalesMilestonesForCommercializedProducts
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Collaboration, Discovery, Development And Commercialization Agreements + References No definition available. + Details
Name: | sny_CommitmentsRelatedToCollaborationDiscoveryDevelopmentAndCommercializationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Maximum Payments For Projects Under Collaboration Agreement + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMaximumPaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Related To Milestone Payments For Projects Under Collaboration Agreements + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments related to r and d payments contingent upon attainment of sales targets. + References No definition available. + Details
Name: | sny_CommitmentsRelatedToResearchAndDevelopmentPaymentsContingentUponAttainmentOfSalesTargets
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Commitments Related To Research And Development Relating To Projects In Research Phase + References No definition available. + Details
Name: | sny_CommitmentsRelatedToResearchAndDevelopmentRelatingToProjectsInResearchPhase
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Consideration Collaboration Agreements + References No definition available. + Details
Name: | sny_ContingentConsiderationCollaborationAgreements
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Cumulative Development Costs Incurred + References No definition available. + Details
Name: | sny_CumulativeDevelopmentCostsIncurred
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number Of Immunology Or Inflammation Targets Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfImmunologyOrInflammationTargetsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Novel Small Molecule Candidates To Be Developed Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfNovelSmallMoleculeCandidatesToBeDevelopedUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Oncology Targets Under Collaboration Agreement + References No definition available. + Details
Name: | sny_NumberOfOncologyTargetsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number Of Targets That Encompass All Diseases Areas + References No definition available. + Details
Name: | sny_NumberOfTargetsThatEncompassAllDiseasesAreas
Namespace Prefix: | sny_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Off Balance Sheet Commitments Received In Respect Of Disposals Proceeds Receivable And Contingent Consideration On Divestments + References No definition available. + Details
Name: | sny_OffBalanceSheetCommitmentsReceivedInRespectOfDisposalsProceedsReceivableAndContingentConsiderationOnDivestments
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Percentage of cumulative development costs reimbursed. + References No definition available. + Details
Name: | sny_PercentageOfCumulativeDevelopmentCostsReimbursed
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of future development expense funded by company. + References No definition available. + Details
Name: | sny_PercentageOfFutureDevelopmentExpenseFundedByCompany
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of future development expense funded by other party. + References No definition available. + Details
Name: | sny_PercentageOfFutureDevelopmentExpenseFundedByOtherParty
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of profit share on counter parties profit. + References No definition available. + Details
Name: | sny_PercentageOfProfitShareOnCounterpartiesProfit
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Provisions and other non-current liabilities. + References No definition available. + Details
Name: | sny_ProvisionsAndOtherNonCurrentLiabilitiesLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Reserve percentage of pandemic vaccines. + References No definition available. + Details
Name: | sny_ReservePercentageOfPandemicVaccines
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Share of operating expenses and cost of producion to joint partner payable period. + References No definition available. + Details
Name: | sny_ShareOfOperatingExpensesAndCostOfProductionToJointPartnerPayablePeriod
Namespace Prefix: | sny_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Transfer percentage of pandemic vaccines. + References No definition available. + Details
Name: | sny_TransferPercentageOfPandemicVaccines
Namespace Prefix: | sny_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upfront payments. + References No definition available. + Details
Name: | sny_UpfrontPayments
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_AblynxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_KymabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CategoriesOfRelatedPartiesAxis=sny_WorldHealthOrganizationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_JointVenturesAxis=ifrs-full_JointVenturesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_DiceMoleculesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_LonzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_ABLBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AdageneIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_BlackstoneLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_IGMBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_SkyhawkTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_MiReculeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_InnatePharmaSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_ExscientiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AtomwiseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_ScribeTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_InsilicoMedicineMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_RegeneronPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |